Drug-specific T-cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat.
Paul J ThomsonLaila KafuXiaoli MengJan SnoeysAn De BondtDries De MaeyerHans WilsLaurent LeclercqPetra VinkenDean John NaisbittPublished in: Allergy (2020)
The detection of atabecestat metabolite-responsive T-cell clones activated via a pharmacological interactions pathway in patients with liver injury is indicative of an immune-based mechanism for the observed hepatic enzyme elevations.